Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study
Ki Hoon Kim(Inje University Sanggye Paik Hospital), Ho Jin Kim(National Cancer Center), Hee Jo Han(Yonsei University), Yeon Hak Chung(Samsung Medical Center), Jae‐Won Hyun(Seoul National University Hospital), Young‐Min Lim(Ulsan College), Young Nam Kwon(Yonsei University), Eun‐Jae Lee(Ulsan College), Hyunjin Kim(Samsung Medical Center), Su‐Hyun Kim(National Cancer Center), Sung‐Min Kim(Seoul National University Hospital), Seung Woo Kim(Ulsan College), Seong Ho Jeong(Inje University Sanggye Paik Hospital), Ju‐Hong Min(Samsung Medical Center), Ha Young Shin(Yonsei University)
Cited by 8
Related Papers
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284
A New Subtype Classification of Ischemic Stroke Based on Treatment and Etiologic Mechanism
|European Neurology|2006|121